Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Intensive lipid-lowering with rosuvastatin (Crestor) for not even two full years significantly and dramatically reduced the rate of myocardial infarction, stroke, and cardiovascular death in "apparently healthy men and women," researchers reported here.
Participants who took 20 mg of rosuvastatin for 1.9 years reduced median LDL cholesterol to 55 mg/dL, down from a median of 108 mg/dL, said Paul M. Ridker, M.D., of Brigham and Women's Hospital in Boston and principal investigator of the JUPITER trial. The corresponding reduction in the rate of MI stroke, arterial revascularization, or cardiovascular death was 44% (P<0.00001).
Dr. Ridker presented the findings at a late-breaking clinical trials session at the American Heart Association meeting here and the findings were published concurrently online in the New England Journal of Medicine.
Participants who took 20 mg of rosuvastatin for 1.9 years reduced median LDL cholesterol to 55 mg/dL, down from a median of 108 mg/dL, said Paul M. Ridker, M.D., of Brigham and Women's Hospital in Boston and principal investigator of the JUPITER trial. The corresponding reduction in the rate of MI stroke, arterial revascularization, or cardiovascular death was 44% (P<0.00001).
Dr. Ridker presented the findings at a late-breaking clinical trials session at the American Heart Association meeting here and the findings were published concurrently online in the New England Journal of Medicine.
Labels: from the literature
posted by Connie Schardt at
9:39 AM
0 Comments:
Post a Comment
<< Home